Lucosky Brookman Serves as Special Counsel to NeuroOne Medical Technologies In Connection with Uplisting to NASDAQ
Lucosky Brookman LLP is pleased to announce that it served as special counsel to NeuroOne Medical Technologies (NASDAQ:NMTC) and assisted the Company in its uplisting to the NASDAQ Capital Market. The Firm was delighted to help the Company reach the next level, as it begins trading on NASDAQ.
“The team at NeuroOne has worked relentlessly for the past four years to position the company to accomplish this major milestone,” NeuroOne CEO Dave Rosa said. “NASDAQ has an established reputation for being an exchange associated with emerging growth stocks, and we believe our uplisting will elevate the company’s corporate profile with current and prospective investors, and the financial community as a whole.”
“As the company continues to grow, we are hopeful our Nasdaq uplisting will generate even greater interest in our company from leading institutional investment firms across the broader national and international investment community.”